Targeting Early Dementia: Using Lipid Cubic Phase Nanocarriers to Cross the Blood–Brain Barrier

Over the past decades, a frequent co-morbidity of cerebrovascular pathology and Alzheimer’s disease has been observed. Numerous published studies indicate that the preservation of a healthy cerebrovascular endothelium can be an important therapeutic target. By incorporating the appropriate drug(s) into biomimetic (lipid cubic phase) nanocarriers, one obtains a multitasking combination therapeutic, which targets certain cell surface scavenger receptors, mainly class B type I (i.e., SR-BI), and crosses the blood–brain barrier. This targeting allows for various cell types related to Alzheimer’s to be simultaneously searched out for localized drug treatment in vivo.